One of the first actions by GSK’s recently appointed Chief Scientific Officer, Tony Wood, was to expand its partnership with Tempus with the aim of improving the R&D productivity of large pharmaceutical companies.
US-based Tempus has built a precision medicine platform powered by artificial intelligence and machine learning. The platform sifts through a large library of anonymized patient data, including clinical, molecular, and genomic test results. The aim is to provide drug developers and medical professionals with data tools so patients can benefit from pioneering treatments.
GSK is the latest group of pharmaceutical companies to tap into its resources to discover new drug targets, improve clinical trial design and accelerate patient recruitment.
The two companies have been working together for some time. For example, they began enrolling him in GSK’s open-label Phase 2 PAVO trial of his PARP inhibitor Zejula (niraparib) in January.
In that study, GSK is using Tempus’ TIME Trial Programme. This is a just-in-time network of providers that support patient identification, site activation, and clinical trial enrollment.
GSK said the new deal will expand GSK’s access to Tempus’ anonymized patient data and bring greater “scale and detail” to the partnership. statement.
Wood (pictured above), who was appointed CSO-elect at GSK in January and assumed the position in August, said the Tempus platform is “at the intersection of genomics and machine learning, across both early and early detection. It complements the work our team is already doing: clinical trials.”
GSK has already scored well among the top 14 pharmaceutical companies when it comes to R&D efficiency, ranking third behind Pfizer and Novartis. analysis Last year’s R&D productivity survey looked at activity over the last 20 years.
However, as the company itself has admitted in recent years, it has performed poorly, especially when it comes to late-stage program offerings. Wood said he stepped down earlier this year to take over his CEO role at his lab, Altos in the United States, to continue efforts to regain productivity that began under his predecessor Hal His Baron. I participated this year.
Wood said this morning that with GSK’s investments in genetics, functional genomics and AI/ML, the company has more than doubled the number of targets in its initial portfolio since 2017, increasing the percentage of targets with genetic support to 70. He said he increased it. %.
GSK has made a $70 million down payment to expand the partnership, with an undisclosed minimum three-year funding commitment that can be extended up to five years if required.